Table 3.

Summary of patient outcomes

No.	Age (yrs)	BaselinePSA (ng/ml)	Gleason score	Clinical stage	Preoperative PSA (ng/ml)	Pathological stage	Surgical margin	Pathological change	PSA progression (mo)
1	58	17.0	7	T2aN0	0.083	T2bN0	negative	2	No
2	68	21.5	7	T1cN0	0.078	T2bN0	negative	2	No
3	69	15.0	9	T2aN0	0.045	T2aN0	negative	2	No
4	69	23.4	6	T3aN0	0.143	T2bN0	negative	2	No
5	67	42.9	9	T3aN0	0.133	T2bN0	negative	2	No
6	67	5.1	10	T1bN0	0.002	T0N0	negative	3b	No
7	57	35.9	9	T3aN1	0.056	T3bN1	negative	1	6
8	64	28.3	9	T3aN0	0.084	T2bN0	negative	2	No
9	58	45.1	8	T3aN1	0.071	T3bN1	negative	2	No
10	66	37.8	7	T3bN0	0.11	T3bN1	negative	1	6
11	58	61.2	10	T4N0	0.52	T4N1	negative	1	7
12	62	30.7	5	T1cN0	0.498	T2aN0	negative	2	No
13	67	77.0	10	T2bN0	0.335	T3bN0	negative	1	6
14	67	21.4	9	T2bN0	0.132	T2bN0	negative	2	No
15	63	5.4	9	T2aN0	0.132	T2aN0	negative	1	No
16	68	17.3	9	T2cN0	0.036	T0N0	negative	3b	No
17	71	25.3	7	T1cN0	0.017	T2aN0	negative	2	No
18	67	79.8	9	T1cN0	0.932	T2bN0	negative	0b	No